<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240811062722N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-04</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness and Side Effects of Hydrogen Peroxide for Local Hemostasis in Neurosurgery</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness and Side Effects of Hydrogen Peroxide Use in Establishing Local Hemostasis in Neurosurgical Procedures: A Clinical Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/94546</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Computer-generated random allocation sequence; allocation concealed; balanced for sex, age and diagnosis, Blinding description: Outcome assessors are blinded to group allocation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Local hemostasis during neurosurgical procedures.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: local irrigation of the surgical field with 500 mL of 3% hydrogen peroxide, plus standard hemostatic measures. Intervention 2: Control group: standard hemostatic measures without hydrogen peroxide.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The individual participant data (IPD) will include de-identified baseline patient characteristics, neurosurgical diagnoses and procedure-related information, treatment allocation, intraoperative blood-loss variables, and the prespecified efficacy and safety outcomes, including total blood loss, postoperative rebleeding, surgical site infection, venous gas embolism, postoperative pneumocephalus, and trigeminocardiac reflex. De-identified data from all 96 randomized participants will be made available, subject to applicable ethical and confidentiality requirements.

The following supporting documents will also be shared: the final study protocol and its amendments, the statistical analysis plan (SAP), a blank and unsigned version of the informed consent form, the final clinical study report containing aggregated results, statistical analysis codes developed using R and SPSS (if generated), and the study data dictionary.

All direct and indirect personal identifiers will be removed or appropriately modified before data sharing. No identifiable medical records or signed participant consent forms will be disclosed.

When:
The final study protocol and amendments, statistical analysis plan, blank informed consent form, data dictionary, statistical analysis codes, and final clinical study report will be made available upon publication of the primary study results.

De-identified individual participant data and accompanying metadata will become available six months after publication of the primary study results and will remain accessible for at least five years thereafter. Data access will be subject to the necessary ethical and institutional approvals and execution of a data use agreement, where applicable.

To whom:
Qualified researchers affiliated with universities, research centers, medical institutions, or other recognized research organizations may request access to the study data and supporting documents, regardless of their country of residence. Requests from independent researchers or individuals affiliated with non-academic institutions may also be considered, provided that they demonstrate appropriate scientific qualifications and comply with ethical and confidentiality requirements. All requests will be reviewed by the principal investigator and the research team before approval.

Conditions:
The shared data and documents may be used exclusively for scientifically valid research purposes, including secondary analyses, validation of study findings, replication of results, comparative research, additional investigations, and systematic reviews and meta-analyses.

Applicants must provide their research objectives, research questions or hypotheses, proposed methodology, and statistical analysis plan. Approval from the relevant ethics committee and execution of a data use agreement may be required, as applicable.

Any attempt to re-identify participants, link the dataset to identifiable personal information, transfer the data to unauthorized third parties, or use the data for purposes beyond the approved research objectives is strictly prohibited. All recipients must maintain data confidentiality and security and appropriately acknowledge and cite the original study in any resulting publications.

Where to obtain:
Formal data access requests should be submitted by email to Dr. Farhad Mirzaei, First Academic Supervisor and Scientific Lead of the Study, Department of Neurosurgery, Faculty of Medicine, Tabriz University of Medical Sciences, Imam Reza Hospital, Tabriz, Iran.

Email: golzar.farhad@yahoo.com

Each request should include the applicant's details, institutional affiliation, research objectives, and relevant supporting scientific documents. All requests will be reviewed by the research team, and the decision will be communicated to the applicant.

How to obtain:
Upon receipt of a request, the research team will assess the applicant's scientific qualifications, institutional affiliation, research objectives, and the compatibility of the proposed project with ethical requirements and data use conditions.

Applicants must provide a brief description of their research question, proposed analytical methods, requested variables, and, where applicable, approval from their institutional ethics committee. Following approval, a data use agreement must be completed and signed.

An initial response will be provided within 30 working days after receipt of a complete application. Upon approval and completion of all applicable ethical and administrative requirements, the requested data and documents will be provided through a secure data transfer method within an additional 30 working days. Incomplete requests or requests that do not comply with ethical and confidentiality requirements may be declined.

Comments:
Data and document sharing will be conducted to promote research transparency, reproducibility of findings, and further scientific investigations. All datasets will undergo appropriate de-identification and disclosure risk assessment before being shared. Access will be provided exclusively through a controlled access mechanism in compliance with ethics committee approvals and the regulations of Tabriz University of Medical Sciences. Recipients will be responsible for maintaining confidentiality and ensuring appropriate use of the shared data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Pouya Moayedi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.107,Impasse Mousavi 2, Pashaei St, Tabriz Town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 87 3366 6233</telephone>
        <email>moydip@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pouya Moayedi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.107,Impasse Mousavi 2, Pashaei St, Tabriz Town</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614756</zip>
        <telephone>+98 87 3366 6233</telephone>
        <email>moydip@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis requiring neurosurgical surgery
Age 18-70 years; informed consent from the patient or first-degree relative/legal guardian</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Known allergy to hydrogen peroxide; known pre-existing cardiac disease
History of venous thromboembolism</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G97.31</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: local irrigation of the surgical field with 500 mL of 3% hydrogen peroxide, plus standard hemostatic measures</i_keyword>
      <i_keyword>Control group: standard hemostatic measures without hydrogen peroxide</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total intraoperative blood loss (mL), estimated from suction canister volume at the end of surgery. Timepoint: End of surgery (immediately postoperatively). Method of measurement: Suction canister volume minus irrigation volume, recorded on the intraoperative anesthesia record.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Surgical site infection (SSI) rate. Timepoint: Postoperative follow-up period. Method of measurement: Regular clinical wound examination (swelling, erythema, tenderness, purulent discharge) and systemic signs of infection, recorded on a checklist.</sec_outcome>
      <sec_outcome>Postoperative rebleeding rate. Timepoint: Postoperative follow-up period. Method of measurement: Periodic follow-up visits and review of medical records for re-bleeding events, recorded on checklist.</sec_outcome>
      <sec_outcome>Adverse events: venous air embolism, postoperative pneumocephalus, and trigeminocardiac reflex. Timepoint: Intraoperative and postoperative follow-up period. Method of measurement: Anesthesia records during surgery (VAE, TCR) and postoperative imaging (pneumocephalus), recorded on follow-up checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-14</approval_date>
        <contact_name>Research Ethics Committees of Tabriz University of MedicalSciences</contact_name>
        <contact_address>Golgasht st. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
